Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet‑activating factor‑mitogen‑activated protein kinase axis

Song,Min; Zhang,Heng; Chen,Zhitao; Yang,Jing; Li,Jie; Shao,Sue; Liu,Jing

doi:10.3892/etm.2020.9460

Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet‑activating factor‑mitogen‑activated protein kinase axis

Authors:
- Min Song
- Heng Zhang
- Zhitao Chen
- Jing Yang
- Jie Li
- Sue Shao
- Jing Liu
View Affiliations

Affiliations: Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: November 10, 2020 https://doi.org/10.3892/etm.2020.9460
Article Number: 28

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver fibrosis is a tissue repair process that occurs following various types of chronic liver injury and can develop into liver cirrhosis, portal hypertension or liver cancer without effective treatment. Shikonin has anti‑inflammatory, antiviral and antitumor properties. Furthermore, shikonin has an additional effect of antagonizing tissue and organ fibrosis. The aim of the present study was to evaluate the mechanisms of action underlying shikonin against liver fibrosis. Cell viability was assessed using the Cell Counting Kit‑8 and EdU incorporation assays. Protein and mRNA expression levels were measured via western blotting and immunofluorescence assays, respectively. Apoptosis was examined via flow cytometry and autophagy via transmission electron microscopy. Compared with the control group, shikonin did not significantly alter LX‑2 cell viability at 0.2 µmol/ml, which was used as the intervention concentration. However, shikonin significantly inhibited fibrosis, as indicated by a decrease in the expression of α‑smooth muscle actin and collagen‑I in the TGF‑β + shikonin group compared with the TGF‑β group. The results indicated that shikonin potentially inhibited fibrosis via promoting cell apoptosis and inhibiting autophagy. Additionally, the results of the present study indicated that shikonin downregulated the expression levels of platelet‑activating factor (PAF) in TGF‑β‑treated cells, which subsequently activated the MAPK signaling pathway, leading to enhanced cell apoptosis and reduced autophagy. Collectively, the present study indicated that shikonin promoted cell apoptosis and suppressed autophagy via the PAF‑MAPK axis in LX‑2 cells, thus blocking the development of fibrosis. The results of the present study may provide a potential therapeutic strategy for liver fibrosis.

View Figures

View References

1	Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 7:425–436. 2010.PubMed/NCBI View Article : Google Scholar
2	Zhang X, Cui JH, Meng QQ, Li SS, Zhou W and Xiao S: Advance in anti-tumor mechanisms of shikonin, alkannin and their derivatives. Mini Rev Med Chem. 18:164–172. 2018.PubMed/NCBI View Article : Google Scholar
3	Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011.PubMed/NCBI View Article : Google Scholar
4	Ma X, Yu M, Hao C and Yang W: Shikonin induces tumor apoptosis in glioma cells via endoplasmic reticulum stress, and Bax/Bak mediated mitochondrial outer membrane permeability. J Ethnopharmacol. 263(113059)2020.PubMed/NCBI View Article : Google Scholar
5	Guo C, He J, Song X, Tan L, Wang M, Jiang P, Li Y, Cao Z and Peng C: Pharmacological properties and derivatives of shikonin-A review in recent years. Pharmacol Res. 149(104463)2019.PubMed/NCBI View Article : Google Scholar
6	Nie Y, Yang Y, Zhang J, Cai G, Chang Y, Chai G and Guo C: Shikonin suppresses pulmonary fibroblasts proliferation and activation by regulating Akt and p38 MAPK signaling pathways. Biomed Pharmacother. 95:1119–1128. 2017.PubMed/NCBI View Article : Google Scholar
7	Ding H, Jiang L, Xu J, Bai F, Zhou Y, Yuan Q, Luo J, Zen K and Yang J: Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am J Physiol Renal Physiol. 313:F561–F575. 2017.PubMed/NCBI View Article : Google Scholar
8	Fan C, Dong Y, Xie Y, Su Y, Zhang X, Leavesley D and Upton Z: Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts. Int J Mol Med. 36:985–991. 2015.PubMed/NCBI View Article : Google Scholar
9	Yang J, Wang Z and Chen DL: Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress. Biomed Pharmacother. 93:1343–1357. 2017.PubMed/NCBI View Article : Google Scholar
10	Wang H and Zhang G: Activation of CaMKKβ-AMPK-mTOR pathway is required for autophagy induction by β,β-dimethylacrylshikonin against lung adenocarcinoma cells. Biochem Biophys Res Commun. 517:477–483. 2019.PubMed/NCBI View Article : Google Scholar
11	Tian R, Li Y and Gao M: Shikonin causes cell cycle arrest and induces apoptosis by regulating the EGFR/NF-κB signaling pathway in human epidermoid carcinoma A431 cells. Biosci Rep. 35(e00189)2015.PubMed/NCBI View Article : Google Scholar
12	Wei Y, Li M, Cui S, Wang D, Zhang CY, Zen K and Li L: Shikonin inhibits the proliferation of human breast cancer cells by reducing tumor-derived exosomes. Molecules. 21(777)2016.PubMed/NCBI View Article : Google Scholar
13	Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y, Lv J, Song Z, Li Y, Ji L, et al: Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Biochem Pharmacol. 88:322–333. 2014.PubMed/NCBI View Article : Google Scholar
14	Wang L, Gai P, Xu R, Zheng Y, Lv S, Li Y and Liu S: Shikonin protects chondrocytes from interleukin-1beta-induced apoptosis by regulating PI3K/Akt signaling pathway. Int J Clin Exp Pathol. 8:298–308. 2015.PubMed/NCBI
15	Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, et al: Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. Int J Oncol. 46:963–972. 2015.PubMed/NCBI View Article : Google Scholar
16	Shen M, Chen K, Lu J, Cheng P, Xu L, Dai W, Wang F, He L, Zhang Y, Chengfen W, et al: Protective effect of astaxanthin on liver fibrosis through modulation of TGF-β1 expression and autophagy. Mediators Inflamm. 2014(954502)2014.PubMed/NCBI View Article : Google Scholar
17	Zhu XF, Un XF, Liu GH and Chen FF: Effects of shikonin on the proliferation, migration and differentiation of HaCaT cells mediated by IL-22. J Clin Dermatol. 43:215–218. 2014.
18	Qisen Li, Zeng J, Su M, He Y and Zhu B: Acetylshikonin from Zicao attenuates cognitive impairment and hippocampus senescence in D-galactose-induced aging mouse model via upregulating the expression of SIRT1. Brain Res Bulletin. 137:311–318. 2018.PubMed/NCBI View Article : Google Scholar
19	Wang H and Zhang G: Endoplasmic reticulum stress-mediated autophagy protects against β,β-dimethylacrylshikonin-induced apoptosis in lung adenocarcinoma cells. Cancer Sci. 109:1889–1901. 2018.PubMed/NCBI View Article : Google Scholar
20	Jing H, Sun W, Fan J, Zhang Y, Yang J, Jia J, Li J, Guo J, Luo S and Zheng Y: Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways. Mol Med Rep. 13:3009–3016. 2016.PubMed/NCBI View Article : Google Scholar
21	He C and Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Annual Rev Genet. 43:67–93. 2009.PubMed/NCBI View Article : Google Scholar
22	Mallat A, Lodder J, Teixeira-Clerc F, Moreau R, Codogno P and Lotersztajn S: Autophagy: A multifaceted partner in liver fibrosis. Biomed Res Int 2014: 869390, 2014. urihttps://doi.org/10.1155/2014/869390simplehttps://doi.org/10.1155/2014/869390.
23	Zhang XW, Zhou JC, Peng D, Hua F, Li K, Yu JJ, Lv XX, Cui B, Liu SS, Yu JM, et al: Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation. Autophagy. 16:782–796. 2020.PubMed/NCBI View Article : Google Scholar
24	Liang H, Pan Z, Zhao X, Liu L, Sun J, Su X, Xu C, Zhou Y, Zhao D, Xu B, et al: LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d. Theranostics. 8:1180–1194. 2018.PubMed/NCBI View Article : Google Scholar
25	Lv XX, Wang XX, Li K, Wang ZY, Li Z, Lv Q, Fu XM and Hu ZW: Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents. PLoS One. 8(e68631)2013.PubMed/NCBI View Article : Google Scholar